News
-
-
COMMUNIQUÉ DE PRESSE
Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
Dermapharm Holding SE reports 7.3% rise in unadjusted EBITDA to EUR 147.0 million, driven by organic growth in branded pharmaceuticals segment. High-revenue expected in H2. Full report at https://ir.dermapharm.de/en -
-
-
-
-
-
-
-